First Tracks Biotherapeutics (TRAX) Earnings Date
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
1 of 2 scored quarters beat.
| Report | Est EPS | Act EPS | Surprise | Est rev | Act rev | Rev surp. | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 3, 20268-K, after close · 4:15 pm ET | −0.90 | −0.88 | +2.5% | $0.00 | $0.00 | — | +5.8%next session |
| Aug 12, 20268-K, after close · 4:19 pm ET | −0.74 | −0.95 | −28.4% | $75.0M | $0.00 | −100.0% | −4.6%next session |
| May 14, 20268-K, after close · 4:24 pm ET | — | −1.45c | — | — | $0.00 | — | −6.9%next session |
| Nov 4, 2025 E | — | −1.50 | — | — | $0.00 | — | —estimated date |
| Aug 4, 2025 E | — | −1.47 | — | — | $0.00 | — | —estimated date |
Estimate-vs-actual scoring began Jul 2026 and is still accruing: 2 of the 5 quarters above carry a scored estimate. We never backfill an estimate we didn't observe.
E marks a report date we estimated from the fiscal period end, because we found no results release and no usable filing date for that quarter. Those rows show no reaction: a move measured from a day we guessed is not a reaction to the release, and we would rather leave it blank than publish it.
c Computed by Tenet. The company's diluted figure is not in our data feed for this period, so this is net income attributable to common shareholders divided by the larger of the weighted basic and diluted share counts.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 6 | 4 | 6 | 7 |
| Avg estimate | −0.73 | −0.76 | −3.99 | −3.46 |
| Low estimate | −0.85 | −0.91 | −4.28 | −4.30 |
| High estimate | −0.61 | −0.58 | −3.85 | −2.48 |
| Year-ago EPS | — | −1.45 | — | −3.99E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 0 | 0 | 4 | 0 |
| Avg estimate | $0.00 | $0.00 | $75.0M | $0.00 |
| Low estimate | $0.00 | $0.00 | $75.0M | $0.00 |
| High estimate | $0.00 | $0.00 | $75.0M | $0.00 |
| Year-ago revenue | — | $0.00 | — | $75.0ME |
| Implied growth | — | — | — | −100.0% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −0.73 | −0.76 | −3.99 | −3.46 |
| 7 days ago | −0.75 | — | −4.04 | −3.54 |
| 30 days ago | −0.84 | — | −4.12 | −3.64 |
| 60 days ago | −0.85 | — | −4.21 | −3.78 |
| 90 days ago | −0.80 | — | −3.42 | −2.99 |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus moved $−0.80 → $−0.73 over 90 tracked days, the same quarter at both ends. Per-analyst up/down revision counts aren't in our data feed. We show the bar's actual movement instead of guessing.
Common questions
What were First Tracks Biotherapeutics' latest quarterly earnings?
First Tracks Biotherapeutics reported diluted EPS of −0.88 and revenue of $0.00 on Nov 3, 2026.
How did First Tracks Biotherapeutics' stock move after its last earnings report?
First Tracks Biotherapeutics moved +5.8% in the session after its Nov 3, 2026 report.

